CHMP konkluderede, at de forelagte data kun viser begrænset virkning af veraliprid til behandling af vasomotoriske symptomer knyttet til menopausen.
The CHMP concluded that the data submitted showed only limited effect of veralipride in the treatment of vasomotor symptoms associated with the menopause.